SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date, amended upper-limb data and recent commercial-launch job postings. Many expect approval and anticipate short covering, while others stress that hiring and FDA rare-disease messaging are not proof of a favorable decision and point to the prior setbacks and remaining efficacy questions.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios reported FDA approval of a competing RRP treatment has fueled debate over the threat to Precigens PAPZIMEOS and whether the selloff is an overreaction; traders disagree on the therapies relative advantages and Precigens commercial head start. Attention is also turning to upcoming PRGN-2009 clinical data and a Q3 business update.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Shares are climbing to a fresh 52-week high as traders position ahead of the expected Q3 report, with BRIUMVI sales growth supporting optimism. Some also speculate about a potential buyout or short squeeze, but the takeover chatter is unconfirmed, and others attribute the move to earnings expectations and momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas announced addition to the S&P 500, replacing Kenvue, is drawing attention, with traders weighing index-related buying against a possible sell-the-news reaction. Some posts also raise unverified claims about a DHS-related breach, but they do not appear to be the main catalyst.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares post-TDAPA reimbursement contribution for DefenCath could decline through 2027 is driving the sharp selloff and debate over future revenue. Some traders view the comments as a serious pricing risk, while others argue DaVitas estimates are preliminary and point to CMSs more favorable payment assumptions; several describe the decline as an overreaction.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers upcoming quarterly earnings report is the main focus, with traders watching whether results and guidance can support the recent rally. Sentiment is split between hopes for an earnings beat and renewed strength in big pharma, and concerns about the companys growth outlook and patent expirations.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Lines stronger-than-expected third-quarter results and raised full-year outlook sparked a sharp rally, with traders debating whether heavy short interest could amplify the move. The reaction is mixed: some see evidence of a turnaround, while others point to profit-taking, fuel-cost pressures and lingering concerns about bookings and yields.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial reaching its prespecified 80th death event triggered final analysis and heightened anticipation of topline results for its GPS treatment in AML. Traders are sharply divided: bulls see potential for strong survival data, while skeptics question the trials control-arm assumptions and point to the share-price weakness as a reason for caution.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq selloff has put QQQ in correction territory, with traders linking the pressure to weakness across technology and AI-related stocks, worries about returns on heavy AI spending, and rising-rate concerns. The community is split between bears expecting further losses and dip-buyers anticipating a relief bounce or short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Investors Should Consider These Defensive ETFs Now

Rising inflation, Fed uncertainty and AI-related risks are rattling markets. Explore these defensive ETFs to help navigate volatility while staying invested for the long term. 

Consumer Sentiment Drops in September: ETFs to Consider

Consumer sentiment falls to a four-month low amid persistent inflation and uncertainty. Here are some ETFs that investors may consider.

Should You Invest in the iShares U.S. Utilities ETF (IDU)?

Worried About Lingering Market Volatility? Defensive ETFs to Consider

Markets remain under pressure as geopolitical and economic risks rise. Defensive ETFs could help investors navigate volatility without abandoning growth.

Are Inflation Fears Back? ETFs May Help Protect Your Portfolio

Rising oil prices and geopolitical risks are reigniting inflation fears. Explore ETFs that may help investors build a more resilient portfolio.

Utility ETFs to Buy as Rapid AI Buildout Sparks Energy Crisis

AI's power surge is creating a major growth opportunity for utilities, and ETFs like IDU offer diversified exposure to the trend.

VST Stock Gains Overnight: Bernstein Calls Rising Power Demand ‘Double Barreled Earnings Event’ For Vistra 

Equity

Bernstein initiated coverage with an Outperform rating and a $187 target 


ETFs That May Provide Investors Protection From Market Risks

Geopolitical tensions and tech weakness are fueling volatility in U.S. markets. Explore ETFs for portfolio stability. 

Too Much Tech in Your Portfolio? ETFs to Help You Diversify

The recent rotation out of AI-linked stocks highlights the risks of a narrow market rally. As concentration risk rises, defensive ETFs could help investors build more resilient portfolios.

iShares Trust - iShares U.S. Utilities ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Bernstein’s price target implies an 18% upside for Vistra stock.</li><li>The firm said Vistra’s diverse generation assets position it to benefit from rising electricity demand.</li><li>Bernstein said the U.S. is undergoing a major energy transition, with natural gas supporting near-term needs and renewables serving as the long-term goal.&nbsp;</li></ul>Vistra (VST) inched higher overnight on Tuesday after receiving a bullish initiation from Bernstein, which said the company is well-placed to capitalize on major changes reshaping the U.S. energy landscape.&nbsp;<h2 class="st-heading-2">Bernstein Vouches For VST’s Demand&nbsp;</h2>Analyst Sunaina Ocalan began coverage of Vistra with an ‘Outperform’ rating and a $187 price target, highlighting Vistra’s broad power-generation portfolio as a key advantage. The price target implies an 18% upside to the stock’s last closing price.&nbsp;Bernstein also launched coverage across the power, clean energy, and liquefied natural gas industries, citing the United States' entry into a historic period of energy-system transformation. The firm expects shifts in how electricity is generated, transported, and used throughout the country.&nbsp;According to a McKinsey&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.mckinsey.com/industries/public-sector/our-insights/powering-a-new-era-of-us-energy-demand">report</a>, U.S. electricity consumption is climbing much faster than before, rising about 2.5% to 3% a year after nearly twenty years of being flat. The U.S. Energy Information Administration (EIA) says power demand is poised to reach an all-time high as companies ramp up infrastructure to support the AI boom. Goldman Sachs expects U.S. data centers to use more than twice as much power in 2027 as they did in 2025.&nbsp;Bernstein pointed to Vistra’s collection of generation assets as a differentiating factor and "double-barreled earnings event". The firm believes the company is poised to capture growth from increasing electricity consumption.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260617_121047961_png_f0b4d0b55d.webp" alt="Chart Comparing YTD Performance Of VST Vs. Peers" width="2400" height="1240"><figcaption>Chart Comparing YTD Performance Of VST Vs. Peers</figcaption></figure><a href="https://stocktwits.com/symbol/VST">Vistra’s stock</a> edged 0.2% higher overnight, heading into Wednesday.&nbsp;<h2 class="st-heading-2">Energy Transition Underway</h2>Bernstein described the current environment as a rare restructuring of the nation’s energy framework. According to the firm, natural gas is expected to play a critical role in supporting the transition, while utility companies will be central to building and expanding the infrastructure needed to meet future demand.The firm added that renewable and low-carbon energy sources represent the eventual destination of the ongoing transition. As investment continues to flow into power infrastructure, companies operating across multiple parts of the energy value chain could benefit from changing market dynamics.<h2 class="st-heading-2">VST Stock: Retail Traders' View&nbsp;</h2>On Stocktwits, retail sentiment around the stock turned to ‘extremely bearish’ from ‘bearish’ territory the previous day, with a 300% rise in message volume in 24 hours.&nbsp;A user&nbsp;<a href="https://stocktwits.com/DetectiveBullBear/message/656601865">said</a>, “This has been an incredible instrument for swing trading this year. Surprised this is still under 180s.”Another user&nbsp;<a href="https://stocktwits.com/bullishforeverbrah/message/656589918">said</a>, “When the Cogentrix acquisition completes, it's gonna moon.”VST stock has declined over 1% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-mu-wdc-lion-stocks-surge-to-52-week-highs-today/cZK0SaSR7Ib">Why Did MU, WDC, LION Stocks Surge To 52-Week Highs Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a mobile phone with the logo of American energy company Vistra Corp. is seen in front of business website. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Vistra (VST) inched higher overnight on Tuesday after receiving a bullish initiation from Bernstein, which said the company is well-placed to capitalize on major changes reshaping the U.S. energy landscape.&nbsp;

iShares U.S. Utilities ETF

Vistra Corp

Utilities Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

IDU iShares U.S. Utilities ETF

Fundamentals

Latest IDU News